MI-VAD, Inc. is pleased to announce the appointment of Chris Jensen to our Strategic Advisory Board.

Chris loves the energy, excitement, fun and “yes we can” spirit of start up companies. When the start up phase morphs into rapid growth, commercialisation and starting to change the world then the fun increases. This has translated in founding several high growth Technology companies including Left Technologies (Left.io), RightMesh AG (RightMesh.io) and Left Travel (Left Travel.com).

Over the past decade Chris’s companies won many awards including the Deloitte Fast 50 for Canada (#17 and #12) and the Deloitte Fast 500 for North America (#101 and #92). In addition, Left Technologies is a two-time recipient of Canada’s top 100 Employers.

As either CEO or COO at several companies Chris focuses on helping to align all of the moving parts on a clear, shared, vision. Over the past 20 years each business has been driven by the use of data and market insights to grow through the use of Internet based communication. In today’s world there is an expectation that information will be available, and choices will be made, based on what a person can access via their phone, tablet or laptop. Allowing people to find what they are seeking is Chris’s driving passion.

About MI-VAD:
MI-VAD, Inc. is a privately owned Rochester, Minnesota based company that is continuing its development of a revolutionary mechanical blood circulatory device or blood pump known as a ventricular assist device (or “VAD”) for heart failure patients that is minimally invasive. The Company was born from our CEO’s experience in managing a team of cardiologists and cardiac surgeons providing mechanical circulatory support therapy and cardiac transplantation to patients at a world leading healthcare institution that has been at the forefront in the delivery of advanced therapy for severe and end-stage heart failure. MI-VAD was founded as a result of an awareness of the significant limitations of the currently used VAD platforms, with the aim to create a device that would overcome the clinical shortcomings of the current generation of VADs and would be applicable to all types of heart failure, including both dilated and restrictive cardiomyopathy.

Media Contact:
Paul E. Heney
+971-553305842
paul@mivadinc.com
SOURCE: MI-VAD